Apply to
Rise Health
Apply To Subscribe
Subscription Amount
$10,000+ Quarterly
Subscription Period
4-16 Quarters
Management Fee
2% per year over 10 years
Carry
20%
Admin Fee (annualized)
$2.5k + 0.2% of contributed capital
Invest Account
Select invest account
Note from Jeremy Krell, David Arena, and Aman Kaur
Rise Health Venture Capital
The only inclusion-driven venture fund focused on oral health.
Investment with impact. Rise Health Venture Capital (RISE) delivers on that promise by investing in the untapped talent among founders and owners with minimal access to an equitable distribution of healthcare startup funding and resources, specifically in the oral health space.
Mission
Real inclusion, strength and empowerment for untapped talent and underserved businesses in the oral health space, including, but not limited to, women-, LBGTQ+- and minority-owned businesses.
Values
As the only inclusion-driven venture fund for oral health globally, we invest in founders solving difficult health and oral health problems, requiring the inclusion of ideas from diverse perspectives.
We support healthcare companies directly and indirectly, including general health, with a focus on oral health.
We empower groups that have been historically oppressed in roles such as Owner, Founder, Chairperson, President and CEO, and/or leadership roles (C-suite, Board, senior-level).
We have a broad focus on inclusion of thought, not just represented by people, but by the way in which they do business.
Proven Foundation
Rise Health is built on decades of experience and a track record of backing high-performing founders. We leverage medical and business breakthroughs as well as emerging technologies to improve the oral health and overall healthcare systems.
By leveling the playing field of access to startup capital at competitive terms, RISE can bring many quality products and companies to the next level, most of which may otherwise not be given the opportunity to fully benefit our healthcare systems.
Competitive Advantage
As dentists and well-connected business professionals, specifically in the DSO industry, we have unique access to modern ideas with a complete understanding of the market and how to implement products within it. We know where service and product gaps lie and how new ideas and products will be received. Further, Revere Partners, our partner and first VC fund on oral health, has a longstanding track record of successful investments and exits.
Since before the pandemic, RISE’s founding team has been hard at work on this platform, assembling the key pieces to build a sustainable fund approach. As such, we have access to:
- One-of-a-kind published database of 600-700 oral health startups and their 1200-1400 transactions
- 75+ person team consisting of world-renowned dental leaders and experts
- Proprietary tech stack with built-in management, matching, and scoring infrastructure
- State-of-the-art fund administrative services from AngelList
- 300+ startups in the pipeline, meeting 2-3+ new startups per day globally
- An ecosystem of 15+ services to support startups (executive recruitment, executive coaching, DSO partnerships, VC co-investors, integrations, clinical evaluation and KOL marketing platform, regulatory infrastructure and counsel, IP counsel, industrial design, LMS, and more)
Bottom line: According to the ADA and HOI, in 2018, 32% of dentists were women and 28% were racial/ethnic minorities. In 2008, 23% were women and 22% were minorities. Financially speaking:
- Of Seed and Series A stage oraltech startups, male leaders outweigh female leaders by 85.1% and 81.8%, respectively
- Of rounds $500k-1m and $1m+, male oraltech founders outweigh female oraltech founders by 85.1% and 84.7%, respectively
- Of rounds $2-10m and $10m+, male oraltech founders outweigh female founders by 85.2% and 87.5%, respectively
RISE fills a gap for groups that lack funding and lack of proper valuation for their business in the oral health space.
Spotlight: Overjet
Overjet uses cutting-edge computer vision, data science and dental research to enable patient-focused and evidence-based care delivery. Based on the most recent valuation, the company is worth over $426 million in less than five years. Overjet was founded by Dr. Inam who received a PhD in EECS from MIT.
Previously, she led product development at Q bio, a healthcare startup. Dr. Inam has led the development of AI-driven products at MIT’s Computer Science and Artificial Intelligence Lab and uLink. She has corporate experience in GE and Apple and is the recipient of the MIT Graduate Women of Excellence Award.
The companies featured in this note were selected due to their notoriety in the startup and venture capital community. This list is provided for illustrative purposes only and is not an exhaustive list of all investments made or involving the Fund Leads.
Jeremy Krell, David Arena, and Aman Kaur
Investment Details
Subscription Start Date
April 1, 2024
Minimum Quarterly Subscription
$10,000
Minimum Subscription Period
4 Quarters
Management Fee
Investors pay management fees of 2% per year for the first 10 years.
Management fees are taken as a percentage of the total committed capital. The total management fee is paid out quarterly over the first
four years of the fund's life.
Carry
Twenty percent (20%)
Admin Fee (annualized)
$2.5k + 0.2% of contributed capital
Fees for each quarterly fund in the Rolling Fund Program will vary based on each quarterly fund’s capital contributions since the fee includes a flat fee component. Last quarter, this fund closed $13.4k in capital. Learn more about how to estimate your commitment’s fees at our help center.
Fund Lead Commitment
Jeremy Krell, David Arena, and Aman Kaur's personal subscription per quarter will be at least $1,000 in total. Jeremy Krell, David Arena, and Aman Kaur will satisfy their GP commitment in part by waiving 5% of management fees otherwise owed to them by the fund. The remainder of the commitment will be contributed in cash.
Special Disclosure
The Fund Leads manage a pre-existing fund (the "Pre-Existing Fund"). The Pre-Existing Fund's thesis focuses on private oral care companies without a specific focus. The Fund Leads also anticipate launching a future investment vehicle (the "Future Investment Vehicle") with an investment thesis that will focus on clinical trials and regulatory processes in the oral and healthcare space. The Fund Leads will deploy capital of the Fund, the Pre-Existing Fund, and the Future Investment Vehicle based on how well the investment theses, return profiles, and expected investment timelines of potential investments fit those of the Fund, the Pre-Existing Fund, and the Future Investment Vehicle. The Fund Leads intend to allow all Limited Partners a right to invest in the Pre-Existing Fund and Future Investment Vehicle (to the extent such funds are generally open for investment).
Investor FAQ
How is this program different from venture fund investing?
How do subscriptions work?
How do management and admin fees work?
How does carried interest work?
How do distributions work?
Will a Limited Partner (LP) participate in all investments made by the funds offered through this Program?
Will an LP's percentage ownership of quarterly funds always be the same?
Are LPs guaranteed access to Rise Health's future funds?
How are subscriptions funded?
How does changing or canceling a subscription work?
Who manages these funds?
Do funds in this Program have minimum or maximum investment sizes?
What happens if funds in this Program do not invest their total capital each quarter?
When will LPs learn about companies the funds invested in?
Can LPs opt out of specific deals?
Can LPs sell their investment in the fund?
Can LPs redeem their interests in the fund?
When will funds launched under this Program begin deploying capital?
How do I receive tax documents from this Program?
Unanswered questions? Contact AngelList
The performance of past deals or a lead investors' track record is not a guarantee of future returns. Venture capital fund investments are inherently risky and illiquid. Such investments involve a high degree of risk and are suitable only for sophisticated and accredited investors.
AngelList and its affiliates do not provide investment advice to investors. The information on this page should not be relied upon as research, investment advice or a recommendation of any kind. Information on this page is qualified in its entirety by the fund's Limited Partnership Agreement, Private Placement Memorandum and Subscription Agreement, which should be reviewed carefully prior to making an investment decision. Please see these documents for full details regarding risks, minimum investment, fees and expenses. The Fund Lead and the fund's investment advisor have the right to waive or charge additional carry to certain investors. The fund's legal name may be different from the name used above.
This fund may accept new investors after the fund undergoes a valuation update. Certain potential investors in the fund may then have access to materially different information concerning fund value at the time of their investment.
Current or future portfolio companies in this fund may use AngelList's recruiting platform and may pay an affiliate of the fund's investment adviser for premium recruiting tools and services. This may create a potential conflict of interest for the investment adviser, which you will consent to by subscribing to the fund.
Please read the disclosures in full here.
Apply To Subscribe
Subscription Amount
$10,000+ Quarterly
Subscription Period
4-16 Quarters
Management Fee
2% per year over 10 years
Carry
20%
Admin Fee (annualized)
$2.5k + 0.2% of contributed capital
Invest Account
Select invest account